BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:3316-3321. [PMID: 21788562 DOI: 10.1200/jco.2010.33.3757] [Cited by in Crossref: 168] [Cited by in F6Publishing: 192] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu Z, Li Y, Wang L, Hao X, Ying J, Li J, Xing P. Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGS.. [DOI: 10.21203/rs.3.rs-2486337/v1] [Reference Citation Analysis]
2 Li D, Jiang H, Jin F, Pan L, Xie Y, Zhang L, Li C. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients. Genes Genomics 2023;45:93-102. [PMID: 36445572 DOI: 10.1007/s13258-022-01326-w] [Reference Citation Analysis]
3 Yang X, Yao Y, Zhu Q. A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review. Heliyon 2022;8:e12080. [DOI: 10.1016/j.heliyon.2022.e12080] [Reference Citation Analysis]
4 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
5 Cheng H, Guo Z, Zhang X, Wang XJ, Li Z, Huo WW, Zhong HC, Li XJ, Wu XW, Li WH, Chen ZW, Wu TC, Gan XF, Zhong BL, Lyubetsky VA, Rusin LY, Yang J, Zhao Q, Cao QD, Yang JR. Lack of evolutionary convergence in multiple primary lung cancer suggests insufficient specificity of personalized therapy. J Genet Genomics 2022:S1673-8527(22)00249-1. [PMID: 36414223 DOI: 10.1016/j.jgg.2022.11.005] [Reference Citation Analysis]
6 Zhang M, Tang Y, Wang J, Liu Q, Xia B. Lung adenocarcinoma relapse with emerging EGFR mutation following complete response of small cell lung cancer warrants routine re-biopsy: A case report. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1024655] [Reference Citation Analysis]
7 Fan H, Liu H, Lv Y, Song Y. AS-tDR-007872: A Novel tRNA-Derived Small RNA Acts an Important Role in Non-Small-Cell Lung Cancer. Comput Math Methods Med 2022;2022:3475955. [PMID: 35756407 DOI: 10.1155/2022/3475955] [Reference Citation Analysis]
8 Yang L, Xu P, Li M, Wang M, Peng M, Zhang Y, Wu T, Chu W, Wang K, Meng H, Zhang L. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs. Front Oncol 2022;12:894323. [DOI: 10.3389/fonc.2022.894323] [Reference Citation Analysis]
9 Cao P, Li Y, Shi R, Yuan Y, Gong H, Zhu G, Zhang Z, Chen C, Zhang H, Liu M, Pan Z, Liu H, Chen J. Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer. Front Chem 2022;10:837987. [PMID: 35402377 DOI: 10.3389/fchem.2022.837987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Selvarajan G, Jayachandran PK. Dual driver in non-small cell lung carcinoma – therapeutic dilemma. IJMIO 2021;7:16-19. [DOI: 10.25259/ijmio_22_2021] [Reference Citation Analysis]
11 Geng QS, Shen ZB, Zheng YY, Xue WH, Li LF, Zhao J. Precise medication for tumor patients in the context of mental stress. Cell Transplant 2021;30:9636897211049813. [PMID: 34719974 DOI: 10.1177/09636897211049813] [Reference Citation Analysis]
12 Chen M, Huang W, Yang D, Huang J, Li G, Wang X, Xiao N, Zhang W, Guan J, Wang S, Liu L. ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study. Front Mol Biosci 2021;8:684661. [PMID: 34692766 DOI: 10.3389/fmolb.2021.684661] [Reference Citation Analysis]
13 Peng J, Zhao X, Zhao K, Meng X. Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation. Front Oncol 2021;11:731429. [PMID: 34631564 DOI: 10.3389/fonc.2021.731429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Liao J, Li Y, Liu C, Long Q, Wang J. Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment. Front Oncol 2021;11:696881. [PMID: 34169002 DOI: 10.3389/fonc.2021.696881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Wang Q, Gao W, Gao F, Jin S, Qu T, Lin F, Zhang C, Zhang J, Zhang Z, Chen L, Guo R. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting. BMC Cancer 2021;21:602. [PMID: 34034713 DOI: 10.1186/s12885-021-08291-9] [Reference Citation Analysis]
16 Shi X, Dong X, Zhai J, Liu X, Lu D, Ni Z, Wu H, Cai K. Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer. Front Oncol 2021;11:608608. [PMID: 34109108 DOI: 10.3389/fonc.2021.608608] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Wu M, Hong G, Chen Y, Ye L, Zhang K, Cai K, Yang H, Long X, Gao W, Li H. Personalized drug testing in a patient with non-small-cell lung cancer using cultured cancer cells from pleural effusion. J Int Med Res 2020;48:300060520955058. [PMID: 32954884 DOI: 10.1177/0300060520955058] [Reference Citation Analysis]
18 Chen RL, Sun LL, Cao Y, Chen HR, Zhou JX, Gu CY, Zhang Y, Wang SY, Hou W, Lin LZ. Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients. Front Oncol 2021;11:629394. [PMID: 33912453 DOI: 10.3389/fonc.2021.629394] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
19 Wang X, Liu Y, Meng Z, Wu Y, Wang S, Jin G, Qin Y, Wang F, Wang J, Zhou H, Su X, Fu X, Wang X, Shi X, Wen Z, Jia X, Qin Q, Gao Y, Guo W, Lu S. Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer. Ann Transl Med 2021;9:635. [PMID: 33987333 DOI: 10.21037/atm-20-7155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Wang L, Shi T, Feng L, Fan Z, Xu X, Zhou X, Zhang X, Han J, Jing L, Liu J, Shan Y, Liu F, Zuo J, Wang Y. The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer. Cancer Manag Res 2021;13:2613-22. [PMID: 33776479 DOI: 10.2147/CMAR.S298579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lin CC, Wu CY, Tseng JT, Hung CH, Wu SY, Huang YT, Chang WY, Su PL, Su WC. Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC. Biomedicines 2021;9:243. [PMID: 33671000 DOI: 10.3390/biomedicines9030243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Bilgin B, Şendur MAN, Yücel Ş, Hizal M, Güner G, Akyürek N, Erol C, Akıncı MB, Dede DŞ, Yalçın B, Kılıçkap S. The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. J Cancer Res Clin Oncol 2021;147:2637-43. [PMID: 33528638 DOI: 10.1007/s00432-021-03546-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Gieszer B, Megyesfalvi Z, Dulai V, Papay J, Kovalszky I, Timar J, Fillinger J, Harko T, Pipek O, Teglasi V, Regos E, Papp G, Szallasi Z, Laszlo V, Renyi-Vamos F, Galffy G, Bodor C, Dome B, Moldvay J. EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. Transl Lung Cancer Res 2021;10:662-74. [PMID: 33718012 DOI: 10.21037/tlcr-20-814] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. Mol Cancer 2021;20:17. [PMID: 33461557 DOI: 10.1186/s12943-021-01307-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 12.5] [Reference Citation Analysis]
25 An S, Camarillo JM, Huang TY, Li D, Morris JA, Zoltek MA, Qi J, Behbahani M, Kambhampati M, Kelleher NL, Nazarian J, Thomas PM, Saratsis AM. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma. J Exp Clin Cancer Res 2020;39:261. [PMID: 33239043 DOI: 10.1186/s13046-020-01773-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
26 Geng Y, Mei Y, Xi Y, Yu J, Meng K, Zhang T, Ma W. Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations. Onco Targets Ther 2020;13:11089-95. [PMID: 33149620 DOI: 10.2147/OTT.S266477] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Lv C, Ma Y, Feng Q, Lu F, Chi Y, Wu N, Fang J, Yang Y. Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. J Thorac Dis 2020;12:5324-35. [PMID: 33209366 DOI: 10.21037/jtd-20-1265] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Chen H, Liu M, Dai Z, Li S, Luo Y, Wang Y, Su W, Cai W, Yang D, Huang J, Yang Z. Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma. Transl Lung Cancer Res 2020;9:1225-34. [PMID: 32953500 DOI: 10.21037/tlcr-20-679] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Ye J, Lin M, Zhang C, Zhu X, Li S, Liu H, Yin J, Yu H, Zhu K. Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications. Biomed Rep 2020;13:43-8. [PMID: 32440349 DOI: 10.3892/br.2020.1303] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
30 Lin C, Ren Z, Yang X, Yang R, Chen Y, Liu Z, Dai Z, Zhang Y, He Y, Zhang C, Wang X, Cao W, Ji T. Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. Cancer Lett 2020;472:81-96. [PMID: 31838083 DOI: 10.1016/j.canlet.2019.12.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
31 Zhang Y, Shen WX, Zhou LN, Tang M, Tan Y, Feng CX, Li P, Wang LQ, Chen MB. The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China. Biomed Res Int 2020;2020:9387167. [PMID: 32047821 DOI: 10.1155/2020/9387167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Yin X, Xia J, Sun Y, Zhang Z. CHCHD2 is a potential prognostic factor for NSCLC and is associated with HIF-1a expression. BMC Pulm Med 2020;20:40. [PMID: 32054470 DOI: 10.1186/s12890-020-1079-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
33 Yin K, Feng HB, Li LL, Chen Y, Xie Z, Lv ZY, Guo WB, Lu DX, Yang XN, Yan WQ, Wu YL, Zhang XC. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma. Thorac Cancer 2020;11:346-52. [PMID: 31794146 DOI: 10.1111/1759-7714.13271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
34 Tian T, Zhang P, Zhong F, Sun C, Zhou J, Hu W. Nomogram construction for predicting survival of patients with non-small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268 patients. Oncol Lett 2020;19:449-59. [PMID: 31897158 DOI: 10.3892/ol.2019.11112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
35 Mancini I, Simi L, Salvianti F, Castiglione F, Sonnati G, Pinzani P. Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA. Diagnostics (Basel) 2019;9:E117. [PMID: 31547467 DOI: 10.3390/diagnostics9030117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
36 Zhang M, He J, Li T, Hu H, Li X, Xing H, Wang J, Yang F, Ma Q, Liu B, Tang C, Abliz Z, Liu X. Accurate Classification of Non-small Cell Lung Cancer (NSCLC) Pathology and Mapping of EGFR Mutation Spatial Distribution by Ambient Mass Spectrometry Imaging. Front Oncol 2019;9:804. [PMID: 31555581 DOI: 10.3389/fonc.2019.00804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
37 Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. Mol Oncol 2019;13:1827-35. [PMID: 31322322 DOI: 10.1002/1878-0261.12547] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
38 Guo L, Chen Z, Xu C, Zhang X, Yan H, Su J, Yang J, Xie Z, Guo W, Li F, Wu Y, Zhou Q. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer 2019;19:369. [PMID: 31014278 DOI: 10.1186/s12885-019-5555-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
39 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Reference Citation Analysis]
41 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
42 Ai X, Guo X, Wang J, Stancu AL, Joslin PMN, Zhang D, Zhu S. Targeted therapies for advanced non-small cell lung cancer. Oncotarget 2018;9:37589-607. [PMID: 30680072 DOI: 10.18632/oncotarget.26428] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
43 Yin ZJ, Tu HY, Fu M, Zhong WZ, An SJ, Yan HH, Chen HJ, Lin HR, Wu YL. Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer. J Cancer 2018;9:2987-93. [PMID: 30210620 DOI: 10.7150/jca.25679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Sci 2018;109:2852-62. [PMID: 29972716 DOI: 10.1111/cas.13724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
45 Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Cancer Sci 2018;109:2532-8. [PMID: 29807396 DOI: 10.1111/cas.13651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
46 Pedrosa RMSM, Mustafa DAM, Aerts JGJV, Kros JM. Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis. Front Oncol 2018;8:159. [PMID: 29868480 DOI: 10.3389/fonc.2018.00159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
47 Pi C, Xu CR, Zhang MF, Peng XX, Wei XW, Gao X, Yan HH, Zhou Q. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thorac Cancer 2018;9:814-9. [PMID: 29722148 DOI: 10.1111/1759-7714.12651] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
48 Wang H, Zhang M, Tang W, Ma J, Wei B, Niu Y, Zhang G, Li P, Yan X, Ma Z. Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis. Cancer Biol Ther 2018;19:687-94. [PMID: 29565727 DOI: 10.1080/15384047.2018.1450115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
49 Simon E, Bick T, Sarji S, Shentzer T, Prinz E, Yehiam L, Sabo E, Ben-Izhak O, Hershkovitz D. Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas. Oncotarget 2017;8:45736-49. [PMID: 28501852 DOI: 10.18632/oncotarget.17399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
50 Liang C, Wu Z, Gan X, Liu Y, You Y, Liu C, Zhou C, Liang Y, Mo H, Chen AM, Zhang J. Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing. Yonsei Med J 2018;59:13-9. [PMID: 29214771 DOI: 10.3349/ymj.2018.59.1.13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
51 Zhang Q, Ke E, Niu F, Deng W, Chen Z, Xu C, Zhang X, Zhao N, Su J, Yang J, Yan H, Wu Y, Zhou Q. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. Oncotarget 2017;8:4994-5002. [PMID: 27999211 DOI: 10.18632/oncotarget.14007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
52 Rachiglio AM, Esposito Abate R, Sacco A, Pasquale R, Fenizia F, Lambiase M, Morabito A, Montanino A, Rocco G, Romano C, Nappi A, Iaffaioli RV, Tatangelo F, Botti G, Ciardiello F, Maiello MR, De Luca A, Normanno N. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget 2016;7:66595-605. [PMID: 27448974 DOI: 10.18632/oncotarget.10704] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 12.6] [Reference Citation Analysis]
53 Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Oncotarget 2016;7:64410-20. [PMID: 27418132 DOI: 10.18632/oncotarget.10560] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
54 Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun Y, Zhao J, An T, Duan J, Wu M, Wang J. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget 2016;7:20810-24. [PMID: 26989078 DOI: 10.18632/oncotarget.8021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 65] [Article Influence: 10.4] [Reference Citation Analysis]
55 Zhu Y, Guo Z, Liu Y, Zheng X, Yang G, Zheng G. A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma. Oncol Lett 2018;15:2905-12. [PMID: 29435017 DOI: 10.3892/ol.2017.7679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
56 Chen H, Yang X, Liu H, Ma K, Zhong J, Dong Z, Zhuo M, Wang Y, Li J, An T, Wu M, Wang Z, Zhao J. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma]. Zhongguo Fei Ai Za Zhi 2017;20:589-97. [PMID: 28935011 DOI: 10.3779/j.issn.1009-3419.2017.09.01] [Reference Citation Analysis]
57 Zhu L, Zhang S, Xun Y, Jiang Y, Xia B, Chen X, Wang L, Jiang H, Ma S. Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment. Pathol Oncol Res 2018;24:843-51. [PMID: 28868565 DOI: 10.1007/s12253-017-0286-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
58 Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, Ma J, Liu X, Yu J, Ge H. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget 2017;8:13304-11. [PMID: 28076323 DOI: 10.18632/oncotarget.14515] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
59 Shao Y, Zhong D. [Detection and Clinical Significance of Abundance of EGFR Mutation]. Zhongguo Fei Ai Za Zhi 2017;20:578-83. [PMID: 28855040 DOI: 10.3779/j.issn.1009-3419.2017.08.13] [Reference Citation Analysis]
60 Zhu YJ, Zhang HB, Liu YH, Zhang FL, Zhu YZ, Li Y, Bai JP, Liu LR, Qu YC, Qu X, Chen X, Li Y, Zheng GJ. Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs. Oncotarget 2017;8:13195-205. [PMID: 28061461 DOI: 10.18632/oncotarget.14490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
61 Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. Mol Oncol 2017;11:1263-72. [PMID: 28618197 DOI: 10.1002/1878-0261.12099] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
62 Mao Y, Wu S. ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma. Onco Targets Ther 2017;10:3399-404. [PMID: 28744144 DOI: 10.2147/OTT.S133349] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
63 Xiong L, Cui S, Ding J, Sun Y, Zhang L, Zhao Y, Gu A, Chu T, Wang H, Zhong H, Ye X, Gu Y, Zhang X, Hu M, Jiang L. Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. Oncotarget 2017;8:63846-56. [PMID: 28969034 DOI: 10.18632/oncotarget.19139] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
64 Feng Q, Yang ZY, Zhang JT, Tang JL. Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis. Oncotarget 2017;8:59552-62. [PMID: 28938658 DOI: 10.18632/oncotarget.19110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
65 Gu J, Zang W, Liu B, Li L, Huang L, Li S, Rao G, Yu Y, Zhou Y. Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study. Oncotarget 2017;8:67810-20. [PMID: 28978074 DOI: 10.18632/oncotarget.18866] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
66 Huang SM, Yang JJ, Chen HJ, Wu SP, Bai XY, Zhou Q, Tu HY, Wu YL. Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer. Oncotarget 2017;8:81369-76. [PMID: 29113396 DOI: 10.18632/oncotarget.18759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
67 Zhu YJ, Zhang HB, Liu YH, Zhu YZ, Chen J, Li Y, Bai JP, Liu LR, Qu YC, Qu X, Chen X, Zheng GJ. Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC. Oncol Lett 2017;14:2573-9. [PMID: 28789464 DOI: 10.3892/ol.2017.6425] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
68 Luo D, Ma J, Zhang J, Zhao Y. [Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:415-20. [PMID: 28641700 DOI: 10.3779/j.issn.1009-3419.2017.06.08] [Reference Citation Analysis]
69 de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA. The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. PLoS One 2017;12:e0177822. [PMID: 28520821 DOI: 10.1371/journal.pone.0177822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
70 Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Curr Oncol 2017;24:111-9. [PMID: 28490925 DOI: 10.3747/co.24.3524] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
71 Wang J, Bai H, Hong C, Wang J, Mei TH. Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day. Thorac Cancer 2017;8:312-9. [PMID: 28437026 DOI: 10.1111/1759-7714.12443] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
72 Ni J, Weng L, Liu Y, Sun Z, Bai C, Wang Y. Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance. Oncol Lett 2017;13:4549-57. [PMID: 28599456 DOI: 10.3892/ol.2017.6022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
73 Wang Y, Duan J, Chen H, Bai H, An T, Zhao J, Wang Z, Zhuo M, Wang S, Wang J. Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer. Oncol Lett 2017;13:2425-31. [PMID: 28454414 DOI: 10.3892/ol.2017.5740] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
74 Deng F, Li M, Shan WL, Qian LT, Meng SP, Zhang XL, Wang BL. Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer. Oncol Lett 2017;13:2359-65. [PMID: 28454404 DOI: 10.3892/ol.2017.5711] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
75 Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget 2016;7:6984-93. [PMID: 26755650 DOI: 10.18632/oncotarget.6874] [Cited by in Crossref: 104] [Cited by in F6Publishing: 119] [Article Influence: 14.9] [Reference Citation Analysis]
76 Labots M, Gotink KJ, Dekker H, Azijli K, van der Mijn JC, Huijts CM, Piersma SR, Jiménez CR, Verheul HM. Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer. Exp Mol Med 2016;48:e279. [PMID: 27980342 DOI: 10.1038/emm.2016.114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
77 Xu J, Ding G, Zhang X, Jin B, Lou Y, Zhang Y, Wang H, Wu D, Han B. The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China. Onco Targets Ther 2016;9:6479-84. [PMID: 27799795 DOI: 10.2147/OTT.S119341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
78 Xu E, Yu X, Zeng Q, Qiao G, Xuan Y, Tang Y, Zhu Q, He J. Functional role of lncRNA DB327252 in lung cancer. J Thorac Dis 2016;8:2793-802. [PMID: 27867555 DOI: 10.21037/jtd.2016.10.44] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
79 Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, Yang XN, Wu YL. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. J Hematol Oncol 2016;9:86. [PMID: 27619632 DOI: 10.1186/s13045-016-0316-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
80 Li M, Deng F, Qian LT, Meng SP, Zhang Y, Shan WL, Zhang XL, Wang BL. Association between human papillomavirus and EGFR mutations in advanced lung adenocarcinoma. Oncol Lett 2016;12:1953-8. [PMID: 27602120 DOI: 10.3892/ol.2016.4847] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
81 Tian HX, Zhang XC, Wang Z, Chen JG, Chen SL, Guo WB, Wu YL. Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. Cancer Biol Med 2016;13:68-76. [PMID: 27144063 DOI: 10.28092/j.issn.2095-3941.2015.0094] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
82 Bria E, Pilotto S, Amato E, Fassan M, Novello S, Peretti U, Vavalà T, Kinspergher S, Righi L, Santo A, Brunelli M, Corbo V, Giglioli E, Sperduti I, Milella M, Chilosi M, Scarpa A, Tortora G. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget 2015;6:12783-95. [PMID: 25904052 DOI: 10.18632/oncotarget.3727] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
83 Liu Y, Kim J, Qu F, Liu S, Wang H, Balagurunathan Y, Ye Z, Gillies RJ. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma. Radiology 2016;280:271-80. [PMID: 26937803 DOI: 10.1148/radiol.2016151455] [Cited by in Crossref: 118] [Cited by in F6Publishing: 140] [Article Influence: 16.9] [Reference Citation Analysis]
84 Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol 2016;13:335-47. [PMID: 26483300 DOI: 10.1038/nrclinonc.2015.175] [Cited by in Crossref: 152] [Cited by in F6Publishing: 157] [Article Influence: 19.0] [Reference Citation Analysis]
85 Zhou F, Zhou CC. Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Chin J Cancer 2015;34:310-9. [PMID: 26187152 DOI: 10.1186/s40880-015-0036-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
86 Li L, Zhang Z, Bie Z, Wang Z, Zhang P, Nie X, Li Y, Wang H, Ai B, Cheng G. Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients. Chin J Cancer Res 2015;27:294-300. [PMID: 26157326 DOI: 10.3978/j.issn.1000-9604.2015.05.03] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
87 Xu Q, Zhu Y, Bai Y, Wei X, Zheng X, Mao M, Zheng G. Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction. Onco Targets Ther 2015;8:1533-41. [PMID: 26124670 DOI: 10.2147/OTT.S84938] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
88 Zhong W, Yang X, Yan H, Zhang X, Su J, Chen Z, Liao R, Nie Q, Dong S, Zhou Q, Yang J, Tu H, Wu YL. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol 2015;8:54. [PMID: 25981169 DOI: 10.1186/s13045-015-0151-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
89 Niu FY, Zhong WZ, Zhou Q, Wu YL. Clinical trials for lung cancer in China. Transl Lung Cancer Res 2014;3:311-6. [PMID: 25806317 DOI: 10.3978/j.issn.2218-6751.2014.10.04] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
90 Zhang Q, Zhu L, Zhang J. Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients. BMC Cancer 2015;15:88. [PMID: 25886585 DOI: 10.1186/s12885-015-1056-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
91 Shi Z, Fan Y. [Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. Zhongguo Fei Ai Za Zhi 2015;18:110-6. [PMID: 25676406 DOI: 10.3779/j.issn.1009-3419.2015.02.11] [Reference Citation Analysis]
92 Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N, Le Corre D, Rachiglio AM, Reiman A, Sheils O, Noppen C, Lacroix L, Cree IA, Scarpa A, Ligtenberg MJ, Laurent-Puig P. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer 2015;15:26. [PMID: 25637035 DOI: 10.1186/s12885-015-1015-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
93 Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, Li XB, Zhang Z, Wang WJ, Li LQ, Cai CL. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. Exp Ther Med 2015;9:1383-8. [PMID: 25780439 DOI: 10.3892/etm.2015.2221] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 7.5] [Reference Citation Analysis]
94 Shi Y, Sun Y. Medical management of lung cancer: Experience in China. Thorac Cancer 2015;6:10-6. [PMID: 26273329 DOI: 10.1111/1759-7714.12168] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
95 da Cunha Santos G. Adequacy and Utilization of Small Biopsy Material for Molecular Diagnosis. Diagnosing Non-small Cell Carcinoma in Small Biopsy and Cytology 2015. [DOI: 10.1007/978-1-4939-1607-8_6] [Reference Citation Analysis]
96 Früh M, Zhou Q, Leung L, Mok T. Strategy on Patients with EGFR Mutation. New Therapeutic Strategies in Lung Cancers 2015. [DOI: 10.1007/978-3-319-06062-0_9] [Reference Citation Analysis]
97 Han JY, Lee SH, Lee GK, Yun T, Lee YJ, Hwang KH, Kim JY, Kim HT. Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2015;75:475-83. [PMID: 25552401 DOI: 10.1007/s00280-014-2664-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
98 Shi X, Liang W, Yang W, Xia R, Song Y. Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol 2015;36:3345-54. [PMID: 25524578 DOI: 10.1007/s13277-014-2968-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
99 Becker K, Xu Y. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol 2014; 5(4): 560-567 [PMID: 25302160 DOI: 10.5306/wjco.v5.i4.560] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
100 Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Wu CW, Yang CT, Chen YM, Chang GC. Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma. PLoS One 2014;9:e107160. [PMID: 25215536 DOI: 10.1371/journal.pone.0107160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
101 Zhu X, Liang L, Liu C, Yin W, Chen S, Cao B. [Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations]. Zhongguo Fei Ai Za Zhi 2014;17:155-62. [PMID: 24581168 DOI: 10.3779/j.issn.1009-3419.2014.02.15] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
102 Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 2014;15:453. [PMID: 25222836 DOI: 10.1186/s13059-014-0453-8] [Cited by in Crossref: 145] [Cited by in F6Publishing: 151] [Article Influence: 16.1] [Reference Citation Analysis]
103 Shaozhang Z, Ming Z, Haiyan P, Aiping Z, Qitao Y, Xiangqun S. Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients. Med Oncol 2014;31:926. [PMID: 24748405 DOI: 10.1007/s12032-014-0926-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
104 Steffen JA. Diffusion of molecular diagnostic lung cancer tests: a survey of german oncologists. J Pers Med 2014;4:102-14. [PMID: 25562146 DOI: 10.3390/jpm4010102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
105 Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C, Song Y. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol 2014;35:6073-82. [PMID: 24633887 DOI: 10.1007/s13277-014-1804-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
106 Chen HJ, Yang JJ, Fang LY, Huang MM, Yan HH, Zhang XC, Xu CR, Wu YL. Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer. Thorac Cancer 2014;5:155-61. [PMID: 26766993 DOI: 10.1111/1759-7714.12076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
107 Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705. [PMID: 24429876 DOI: 10.1158/1078-0432.CCR-13-2482] [Cited by in Crossref: 570] [Cited by in F6Publishing: 624] [Article Influence: 63.3] [Reference Citation Analysis]
108 Wei B, Yang K, Zhao J, Chang Y, Ma Z, Dong B, Guo Y, Ma J. Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer. J Exp Clin Cancer Res 2014;33:5. [PMID: 24398248 DOI: 10.1186/1756-9966-33-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
109 Leelatian N, Boonchoo P, Wijitburaphat S, Moolsuwan K, Wongjaroen P, Chinnasang P, Anyamaneeratch K, Ruangchira-Urai R, Poungvarin N. Highly sensitive EGFR mutation detection by specific amplification of mutant alleles. Exp Mol Pathol 2014;96:85-91. [PMID: 24370549 DOI: 10.1016/j.yexmp.2013.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
110 Zhao ZR, Wang JF, Lin YB, Wang F, Fu S, Zhang SL, Su XD, Jiang L, Zhang YG, Shao JY, Long H. Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. Med Oncol 2014;31:810. [PMID: 24338271 DOI: 10.1007/s12032-013-0810-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
111 Roma C, Esposito C, Rachiglio AM, Pasquale R, Iannaccone A, Chicchinelli N, Franco R, Mancini R, Pisconti S, De Luca A, Botti G, Morabito A, Normanno N. Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed Res Int 2013;2013:385087. [PMID: 24364033 DOI: 10.1155/2013/385087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
112 Scarpa A, Sikora K, Fassan M, Rachiglio AM, Cappellesso R, Antonello D, Amato E, Mafficini A, Lambiase M, Esposito C, Bria E, Simonato F, Scardoni M, Turri G, Chilosi M, Tortora G, Fassina A, Normanno N. Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 2013;8:e80478. [PMID: 24236184 DOI: 10.1371/journal.pone.0080478] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 8.3] [Reference Citation Analysis]
113 Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther 2013;6:1481-91. [PMID: 24204163 DOI: 10.2147/OTT.S51887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
114 Sah S, Chen L, Houghton J, Kemppainen J, Marko AC, Zeigler R, Latham GJ. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med 2013;5:77. [PMID: 24001039 DOI: 10.1186/gm481] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 7.0] [Reference Citation Analysis]
115 Vallee A, Sagan C, Le Loupp AG, Bach K, Dejoie T, Denis MG. Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. Int J Oncol 2013;43:1045-51. [PMID: 23934203 DOI: 10.3892/ijo.2013.2056] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
116 Altimari A, de Biase D, De Maglio G, Gruppioni E, Capizzi E, Degiovanni A, D'Errico A, Pession A, Pizzolitto S, Fiorentino M, Tallini G. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther 2013;6:1057-64. [PMID: 23950653 DOI: 10.2147/OTT.S42369] [Cited by in Crossref: 6] [Cited by in F6Publishing: 27] [Article Influence: 0.6] [Reference Citation Analysis]
117 Yu S, Xiao X, Lu J, Qian X, Liu B, Feng J. Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy. PLoS One. 2013;8:e68022. [PMID: 23874486 DOI: 10.1371/journal.pone.0068022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
118 Jiang BY, Zhang XC, Su J, Meng W, Yang XN, Yang JJ, Zhou Q, Chen ZY, Chen ZH, Xie Z, Chen SL, Wu YL. BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. Mol Cancer 2013;12:61. [PMID: 23758992 DOI: 10.1186/1476-4598-12-61] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
119 Zhu J, Cai L, Yang H, Wen Y, Wang J, Rong T, Zhang L. Plasma fibrinogen levels are associated with epidermal growth factor receptor gene mutation in Chinese patients with non-small cell lung cancer. Chin -Ger J Clin Oncol 2013;12:203-209. [DOI: 10.1007/s10330-013-1151-9] [Reference Citation Analysis]
120 Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, Yan S, Wu N, Zheng Q, Li S, Chen J, Wang J, Feng Y, Wang Y, Pei Y, Fang J, Yang Y. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. World J Surg Oncol 2013;11:96. [PMID: 23621919 DOI: 10.1186/1477-7819-11-96] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
121 Wang S, An T, Duan J, Zhang L, Wu M, Zhou Q, Chen J, Zhuo M, Yang L, Wang Y, Bai H, Wang J. Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer. PLoS One 2013;8:e51021. [PMID: 23520442 DOI: 10.1371/journal.pone.0051021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
122 Luo SY, Lam DC. Oncogenic driver mutations in lung cancer. Transl Respir Med 2013;1:6. [PMID: 27234388 DOI: 10.1186/2213-0802-1-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
123 Oxnard GR, Jänne PA. Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. Clin Cancer Res 2013;19:1634-6. [PMID: 23403632 DOI: 10.1158/1078-0432.CCR-13-0169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
124 Angulo B, Conde E, Suárez-Gauthier A, Plaza C, Martínez R, Redondo P, Izquierdo E, Rubio-Viqueira B, Paz-Ares L, Hidalgo M, López-Ríos F. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One 2012;7:e43842. [PMID: 22952784 DOI: 10.1371/journal.pone.0043842] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 6.4] [Reference Citation Analysis]
125 An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012;7:e40109. [PMID: 22768234 DOI: 10.1371/journal.pone.0040109] [Cited by in Crossref: 114] [Cited by in F6Publishing: 136] [Article Influence: 10.4] [Reference Citation Analysis]
126 Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012;17:978-985. [PMID: 22673630 DOI: 10.1634/theoncologist.2011-0385] [Cited by in Crossref: 116] [Cited by in F6Publishing: 136] [Article Influence: 10.5] [Reference Citation Analysis]
127 Liu Y, Liu B, Li XY, Li JJ, Qin HF, Tang CH, Guo WF, Hu HX, Li S, Chen CJ, Liu B, Gao HJ, Liu XQ. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res 2011;30:111. [PMID: 22142557 DOI: 10.1186/1756-9966-30-111] [Cited by in Crossref: 49] [Cited by in F6Publishing: 57] [Article Influence: 4.1] [Reference Citation Analysis]